)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
OssDsign
OssDsign (OSSD) investor relations material
OssDsign Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary3 Nov, 2026
Executive summary
Q3 net sales were SEK 35.7m, down 18.8% YoY reported; stronger summer holidays weighed on demand, while sales improved through the quarter.
Growth plans center on Catalyst awareness, commercial reorganization and clinical evidence; US sales leadership roles were filled.
Financial highlights
Q3 sales were SEK 35.7m vs SEK 44.0m a year earlier, down 18.8% reported and 19.8% in constant currency.
Q3 adjusted EBIT was SEK -6.6m vs -5.3m YoY; reported EBIT was SEK -6.9m vs -5.5m.
Q3 net loss was SEK 5.8m, broadly unchanged YoY; EPS was SEK -0.1.
9M sales were SEK 110.4m, down 13.6% at constant FX and 18.3% reported; adjusted EBIT was SEK -32.0m vs -17.1m.
9M net loss was SEK 28.7m, broadly unchanged YoY; EPS was SEK -0.3.
Outlook and guidance
Strategy remains focused on restoring growth through Catalyst awareness and a stronger US commercial channel; commercial reorganization is expected to support momentum later than initially planned.
MIS Catalyst and Catalyst Strip development continued; a Catalyst labeling-change submission was made in Q3.
Next PROPEL registry data release is expected in Q1 2027; timing for the first patient in the planned level one study is forthcoming.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from OssDsign
- Investor meeting appearance to feature updates on regenerative implants and reconstruction solutions.OSSD
Financial Stockholm - ASCENT25 targets SEK 300–400 million in 2025 sales and operating cash flow positivity in 2024.OSSDStrategy Update
- High fusion rates, U.S. market focus, and sales force overhaul support ambitious 2028 growth targets.OSSDDNB Carnegie Micro Cap Day Conference
- Q2 sales declined year-over-year, but restructuring and innovation support future growth.OSSDQ2 2026
- Property-focused group targets recurring revenues and European growth, leveraging strong cash reserves.OSSDABGSC Investor Days
- Q1 revenue declined 17.1% in SEK and 3.6% in USD, but H2 momentum is expected.OSSDQ1 2026
- Sales up 45% to SEK 180.2M, 96.3% margin, U.S. expansion, aiming for SEK 400M by 2028.OSSDQ4 2025
- Q3 2024 delivered 114% sales growth, 96.9% gross margin, and narrowed losses.OSSDQ3 2024
- Q2 net sales up 143%, gross margin at 93.2%, and major U.S. contracts secured.OSSDQ2 2024
Next OssDsign earnings date
Q4 20269 Feb, 2027
OssDsign
Next OssDsign earnings date
Q4 20269 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
OssDsign AB designs, manufactures, and sells implants and material technology for bone regeneration. The company's products are used to treat bone defects in the hard palate and other areas as well as to support dental implants. The company has strategic relations with several companies across Europe and the US, and markets their products to customers all over the world. OssDsign's aim is to be an innovative and leading specialty pharma player within the fast growing bone reconstruction market by providing products that offer unique opportunities for superior clinical outcomes, thereby adding value for patients, healthcare providers and investors.